Search research articles
Contact Us
Filters
Showing results (91-100 of 151) with videos related to
Page
of 16
Sort By:
Blood
|
April 26, 2003
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
Stefan Suciu, Franco Mandelli, Theo de Witte, et al.
Haematologica
|
May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
Theo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Annals of Hematology
|
August 7, 2014
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies
Margriet Oosterveld, Stefan Suciu, Petra Muus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
Franco Mandelli, Marco Vignetti, Stefan Suciu, et al.
Haematologica
|
March 23, 2010
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia
Anne M Dickinson, Kim F Pearce, Jean Norden, et al.
Blood
|
April 7, 2006
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
Rodrigo Martino, Simona Iacobelli, Ronald Brand, et al.
Haematologica
|
April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry
Bente Houtman, Adele Taylor, Corine Van Marrewijk, et al.
Blood
|
July 3, 2014
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
Leonie I Kroeze, Mariam G Aslanyan, Arno van Rooij, et al.
Transfusion
|
June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Curly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
British Journal of Haematology
|
February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies
Aleksandar Savic, Adele Taylor, Pierre Fenaux, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 151) with videos related to
Sort By:
Page
of 16
Blood
|
April 26, 2003
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
Stefan Suciu, Franco Mandelli, Theo de Witte, et al.
Haematologica
|
May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
Theo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Annals of Hematology
|
August 7, 2014
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies
Margriet Oosterveld, Stefan Suciu, Petra Muus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
Franco Mandelli, Marco Vignetti, Stefan Suciu, et al.
Haematologica
|
March 23, 2010
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia
Anne M Dickinson, Kim F Pearce, Jean Norden, et al.
Blood
|
April 7, 2006
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
Rodrigo Martino, Simona Iacobelli, Ronald Brand, et al.
Haematologica
|
April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry
Bente Houtman, Adele Taylor, Corine Van Marrewijk, et al.
Blood
|
July 3, 2014
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
Leonie I Kroeze, Mariam G Aslanyan, Arno van Rooij, et al.
Transfusion
|
June 27, 2014
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Curly Morris, Liesbeth de Wreede, Marijke Scholten, et al.
British Journal of Haematology
|
February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies
Aleksandar Savic, Adele Taylor, Pierre Fenaux, et al.
Page
of 16